| EUS and cytological EUS-FNA prognostic factors in patients with unresectable pancreatic cancer receiving chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 20422893 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND/AIMS: The incidence of pancreatic cancer is increasing. It is usually diagnosed in an advanced stage despite the improvement in diagnostic techniques. The current study was designed to prospectively analyze several demographic and tumour related variables identified by EUS and EUS-FNA cytology that may affect survival in patients with unresectable pancreatic cancer receiving chemotherapy. METHODOLOGY: The study prospectively included 72 patients diagnosed with pancreatic cancer. Only patients without surgery were selected. All the patients received chemotherapy with the same drug (5-FU). They underwent power Doppler EUS followed by EUS-FNA in all cases. The following information obtained by EUS and EUS-FNA cytology were prepared for inclusion in multivariate survival analysis (tumour localization, portal vein invasion, power Doppler signals presence, collateral circulation, signs of chronic pancreatitis, T and N status, nuclear atypia, nuclear enlargement, pleomorphism, nuclear/cytoplasm ratio, and coarse chromatin). RESULTS: The entire included population was analyzed to identify factors affecting prognosis. The overall Cox model had a significance level of p = 0.032. There were three factors that had a major impact on the survival time of the patients: regional lymph node involvement (p = 0.029), nuclear pleomorphism (p = 0.037) and nuclear enlargement (p = 0.019). CONCLUSIONS: The current pre-treatment evaluation of the pancreatic cancer patients by EUS and EUS-FNA could offer some valuable information for appreciation of patients' future evolution. However, extensive studies are required for a complex prognosis scoring system. |
| | |
Authors:
|
Dan Ionuţ Gheonea; Adrian Săftoiu; Carmen Popescu; Tudorel Ciurea; Sevastiţa Iordache; Monalisa Filip; Anca Maloş |
Related Documents
:
|
19691763 - A proposal for differentiation between early- and advanced-stage autoimmune pancreatiti... 20495653 - Predicting patient survival after pancreaticoduodenectomy for malignancy: histopatholog... 12269913 - Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcino... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Hepato-gastroenterology Volume: 57 ISSN: 0172-6390 ISO Abbreviation: Hepatogastroenterology Publication Date: 2010 Jan-Feb |
Date Detail:
|
Created Date: 2010-04-28 Completed Date: 2010-07-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8007849 Medline TA: Hepatogastroenterology Country: Greece |
Other Details:
|
Languages: eng Pagination: 155-61 Citation Subset: IM |
Affiliation:
|
Research Centre of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Romania. digheonea@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antimetabolites, Antineoplastic / therapeutic use* Biopsy, Fine-Needle Endosonography* Female Fluorouracil / therapeutic use* Follow-Up Studies Humans Male Middle Aged Pancreatic Neoplasms / diagnosis*, drug therapy*, mortality Predictive Value of Tests Prognosis Prospective Studies Survival Analysis Ultrasonography, Interventional* |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 51-21-8/Fluorouracil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reconstruction following pancreaticoduodenectomy for patients who have previously undergone partial ...
Next Document: Spleen-preserving distal pancreatectomy performed laparoscopically.